Natural history and prognostic factors for chronic hepatitis type B.

Fattovich, Giovanna; Brollo, L.; Giustina, G.; Noventa, Franco; Pontisso, Patrizia; Alberti, Alfredo; Realdi, Giuseppe; Ruol, A

doi:10.1136/gut.32.3.294

Cited by 381 publications

(256 citation statements)

References 22 publications

Supporting

Mentioning

242

Contrasting

Unclassified

Order By: Relevance

“…The annual incidence of developing HCC in HBV infected patients at age 70 is 1%. HBV carriers were 100 times more likely to develop HCC than the uninfected patients, but HCC occurs more commonly in patients with established cirrhosis than in noncirrhotic patients (Beasley et al, 1981;Fattovich et al, 1991;Koike et al, 2002;Manno et al, 2004). It has been shown by Beasley at al that the annual incidence of HCC in HBV carriers was 0,5% (Beasley et al, 1981).…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Doğan¹,

Yalçın²,

Koca³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Doğan¹,

Yalçın²,

Koca³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The nature of these interrelationships, together with the influence of various external factors, ultimately determines disease severity and progression [25][26][27]. Accordingly, the natural course of chronic HBV infection consists of distinct phases: an immune-tolerant phase, an immune clearance phase, and an inactive or residual phase [28].…”

Section: Natural Course Of Disease and Hbeag Seroconversionmentioning

confidence: 99%

HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B

2009

View full text Add to dashboard Cite

During the natural history of chronic hepatitis B virus (HBV) infection, the loss of serum hepatitis B e antigen (HBeAg) and the development of anti-HBe antibodies (HBeAg seroconversion) mark a transition from the immune-active phase of disease to the inactive carrier state. This review examines the evidence from natural history and cohort studies on the relationship between HBeAg seroconversion and disease progression. The role of HBeAg seroconversion as an important milestone in the management of HBeAg-positive patients with chronic hepatitis B (CHB), as well as the advantages and disadvantages of administering a finite course of therapy for HBeAg-positive CHB, is also discussed. The evidence from natural history and cohort studies indicates that spontaneous or treatment-induced HBeAg seroconversion is associated with lower rates of disease progression to cirrhosis and hepatocellular carcinoma, a potential of hepatitis B surface antigen seroconversion, and improved survival rates. Updated guidelines developed by major liver associations recommend stopping oral therapy for HBeAgpositive patients who achieve sustained HBeAg seroconversion with polymerase chain reaction-undetectable HBV-DNA on two separate occasions for 6 or more months apart, taking into consideration the individual's clinical and virologic response to therapy, as well as the severity of liver disease. Thus, early induction of HBeAg seroconversion with interferon-based therapy or oral nucleos(t)ide analogues has important clinical and socioeconomic implications for the management of CHB.

show abstract

“…Approximately 1.25 million Americans are chronically infected with hepatitis B [2,3] and are at increased risk for cirrhosis [4,5], hepatic decompensation [6,7], and hepatocellular carcinoma [8][9][10]. In a sample of the general U.S. population, the prevalence of chronic hepatitis B virus (HBV) infection was found to be 0.4% [11].…”

Section: Introductionmentioning

confidence: 99%

Seroepidemiology of hepatitis B virus infection: analysis of mass screening in Hawaii

Tsai

Holck

Ricalde³

2008

Hepatol Int

View full text Add to dashboard Cite

Background Although hepatitis B seroprevalence has been studied extensively in California and New York, detailed information for other high-risk areas in the United States is lacking. To study current prevalence and risk for hepatitis B virus (HBV) infection in Hawaii, we analyzed cross-sectional data from Hawaii residents screened between July 2003 and April 2006. Methods We retrospectively reviewed the screening records of 3,989 participants recruited at health fairs and clinics. Prevalence and risk factors for HBV infection were estimated using univariate and multivariate logistic regression models. Results Total prevalence of hepatitis B surface antigen (HBsAg) was 3.6%. Gender, age, and ethnicity were independently associated with HBsAg seropositivity. In a multivariate logistic regression model, males were at increased risk for HBsAg compared with females (odds ratio [OR] = 1.53, 95% confidence interval [CI]: 1.09-2.16) and persons aged 70 years or older were less likely to test positive than those younger than 30 (OR = 0.25, 95% CI: 0.11-0.61). In addition, multivariate ORs of HBsAg seropositivity were 3.24 (95% CI: 1.04-10.09), 4.13 (95% CI: 1.66-10.29), and 7.47 (95% CI: 2.52-22.11) for Vietnamese, Chinese, and Pacific Islanders, respectively, compared with Whites. Conclusions This study furthers current knowledge of HBV epidemiology in areas with large populations of highrisk immigrants and demonstrates the relevance of screening programs for hepatitis B.

show abstract

Natural history and prognostic factors for chronic hepatitis type B.

Cited by 381 publications

References 22 publications

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B

Seroepidemiology of hepatitis B virus infection: analysis of mass screening in Hawaii

Contact Info

Product

Resources

About